Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-21-017308

Chief Business Development Off sold 416 shares at $61.20 ($25,459)

  • Chief Business Development Off acquired 416 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
BENZENO SHARON Chief Business Development Off 2021-02-19 Option exercise +416 $6.27 $2,608 416 D: show line 1 in the form
BENZENO SHARON Chief Business Development Off 2021-02-19 Sale −416 $61.20 $25,459 0 D: show line 2 in the form
Open-market sales · 416 sh · avg $61.20 · $25,459

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
BENZENO SHARON Chief Business Development Off 2021-02-19 Option exercise · Stock Option (Right to Buy) −416 834 D: show line 3 in the form
Loading xslF345X03/doc4.xml…